| 摘要 |
Disclosed are pharmaceutical composition comprising a) a therapeutically effective amount of a sodium salt of the compound of formula (I) (4-{ 4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl} -cyclohexyl)-acetic acid (Pradigastat), b) one or more surfactants selected from sodium lauryl sulfate, stearic acid, palmitic acid, myristic acid, poloxamers and polyethylene glycols or a combination thereof, and wherein the surfactant is present in an amount which is 0.1 to 5% by weight of the tablet; c) one or more dry binders selected from hydroxypropylmethyl cellulose or hydroxypropyl cellulose, both of medium to high viscosity and wherein the dry binder is present in an amount which is 2 to 20% by weight of the tablet; d) one or more fillers selected from microcrystalline cellulose, Anhydrous Dicalcium Phosphate, Anhydrous Lactose, and combinations thereof, and wherein the filler is present in an amount which is 4% to 85%, by weight of the tablet, and e) one or more disintegrants, wherein the disintegrant is selected from crosscarmellose sodium, cross-linked polyvinyl pyrrolidone, and Sodium Starch Glycollate,; and wherein the disintegrant is present in an amount which is 1-10% by weight of the tablet. Also disclosed is the use of the compositions in the manufacture of a medicament for the treatment of a condition or disorder associated with DGAT1 activity including obesity, diabetes, cardiovascular diseases, neoplastic diseases and dermatological disorders. |
